Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low‐dose dasatinib therapy

Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia... Dear Editor,Tyrosine kinase inhibitors (TKI) are beneficially used for patients with breakpoint cluster region‐abelson (BCR‐ABL) fusion gene‐positive chronic myeloid leukemia (CML); however, elderly patients have a lower tolerance to the standard dose of TKI because of severe adverse events, and therefore a dose reduction or discontinuation of treatment is often required. Recently, low‐dose dasatinib (a dose as low as 20 mg/day) has been shown to be more effective than low‐dose imatinib. We have also reported a similar finding in an elderly chronic phase CML (CML‐CP) patient receiving low‐dose dasatinib (mean dose 5.7 mg/day). In the case of low‐dose therapy, a study of pharmacokinetics and pharmacodynamics is useful to determine the appropriate dosing for a preferable effect without severe adverse events. Although routine monitoring of the therapeutic plasma concentration should be carried out specifically in treatment‐resistant cases for avoiding unnecessary dose escalation, this can also be applied to patients who cannot receive the standard dose because of adverse events. It is controversial whether the trough or the peak concentration relates to a better outcome in the case of imatinib therapy. Regarding dasatinib, this kind of study was limited, and analysis of the intracellular concentration was also shown to be important http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Geriatrics & Gerontology International Wiley

Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low‐dose dasatinib therapy

Loading next page...
 
/lp/wiley/plasma-and-intracellular-concentrations-in-an-elderly-patient-with-P7SrvGrxOT
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Japan Geriatrics Society
ISSN
1444-1586
eISSN
1447-0594
D.O.I.
10.1111/ggi.13238
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Tyrosine kinase inhibitors (TKI) are beneficially used for patients with breakpoint cluster region‐abelson (BCR‐ABL) fusion gene‐positive chronic myeloid leukemia (CML); however, elderly patients have a lower tolerance to the standard dose of TKI because of severe adverse events, and therefore a dose reduction or discontinuation of treatment is often required. Recently, low‐dose dasatinib (a dose as low as 20 mg/day) has been shown to be more effective than low‐dose imatinib. We have also reported a similar finding in an elderly chronic phase CML (CML‐CP) patient receiving low‐dose dasatinib (mean dose 5.7 mg/day). In the case of low‐dose therapy, a study of pharmacokinetics and pharmacodynamics is useful to determine the appropriate dosing for a preferable effect without severe adverse events. Although routine monitoring of the therapeutic plasma concentration should be carried out specifically in treatment‐resistant cases for avoiding unnecessary dose escalation, this can also be applied to patients who cannot receive the standard dose because of adverse events. It is controversial whether the trough or the peak concentration relates to a better outcome in the case of imatinib therapy. Regarding dasatinib, this kind of study was limited, and analysis of the intracellular concentration was also shown to be important

Journal

Geriatrics & Gerontology InternationalWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial